drugset / Trial / NCT06767046
KRAS-Specific Autologous TCR-T Cell Therapy for KRAS Mutation in Advanced Solid Tumors
NaSingle-groupOpen-labelTreatment
Summary
This is a single-center, open-label, single-arm, dose-escalation study aimed at evaluating the safety and preliminary efficacy of KRAS-specific autologous TCR-T cells in patients with advanced solid tumors harboring KRAS G12V mutation.
Timeline
- Start
- 2025-02-18
- Primary completion
- 2028-11-30
- Completion
- 2028-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | KRAS-specific Autologous TCR-T cell injection | Cell therapy | 5e+09 cells | — |
| Subject | KRAS-specific Autologous TCR-T cell injection | Cell therapy | 1e+10 cells | — |
| Subject | KRAS-specific Autologous TCR-T cell injection | Cell therapy | 2e+10 cells | — |
| Background | Cyclophosphamide | Other / unclassified | — | — |
| Background | Fludarabine | Small molecule | — | — |
| Background | aldesleukin | Protein / enzyme biologic | — | — |